Research Progress of mRNA Chimeric Antigen Receptor Cell Therapy
10.11735/j.issn.1004-0242.2025.02.A010
- VernacularTitle:信使RNA嵌合抗原受体细胞疗法的研究进展
- Author:
Xiao ZHOU
1
;
Sheng PAN
;
Sunbin LING
;
Xiao XU
;
Qiang WEI
Author Information
1. 浙江中医药大学第四临床医学院,杭州市第一人民医院,浙江 杭州 310006
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor;
messenger RNA;
cancer;
cell therapy
- From:
China Cancer
2025;34(2):152-158
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,viral vector-mediated chimeric antigen receptor(CAR)cell therapy has emerged as a prominent topic in the field of cancer treatment and has demonstrated significant clinical efficacy in patients with hematological malignancies.However,the permanent expression of CAR induced by this therapy may give rise to severe adverse reactions.In contrast,messenger RNA(mRNA)chimeric antigen receptor therapy is anticipated to become a new generation of safer and more effective treatments due to its lack of insertional mutagenesis and minimal risk of off-tar-get toxicity.This therapeutic approach involves transfecting effector immune cells with CAR-en-coding mRNA to elicit an immune response within the body.It has been employed for treating B-cell malignancies,lymphoma,acute myelogenous leukemia(AML),and other cancers.The continuous optimization of mRNA purification,modification,and transfection technology enhances CAR ex-pression durability,while increasing killing efficiency and expanding the range of action.This pa-per reviews the research advances on CAR-encoding mRNA delivery,its application and advan-tages in cancer therapies.
